PSG.DE PharmaSGP XETRA €29.00 intraday 24 Feb 2026: Oversold bounce trade idea

PSG.DE stock trades at €29.00 on XETRA intraday on 24 Feb 2026 and shows a clear oversold bounce setup after a shallow pullback. Volume today is 12,424.00 shares, about 2.30x the average, which supports a short-term mean-reversion move. The balance of fundamentals and tight liquidity makes PharmaSGP Holding SE a candidate for a tactical rebound trade in Germany’s healthcare group. We outline the technical trigger, valuation context, Meyka AI grade and a disciplined trade plan.

PSG.DE stock intraday snapshot

Price action is compressed between the day low €28.60 and the intraday high €29.00 with previous close at €29.00. Year range shows room for upside with a 52-week high €30.00 and low €19.00. Key market stats: market cap €333,862,500.00, volume 12,424.00, avg volume 5,399.00 and shares outstanding 11,512,500.00.

PSG.DE stock technical bounce setup

Short-term technicals point to an oversold bounce: price is slightly below the 50-day average €28.52 but above the 200-day average €26.10, a constructive configuration. Relative volume at 2.30 supports a quick intraday reversal towards the 50-day mean. ATR is €0.40, so a tight stop under €28.20 keeps risk controlled for a bounce trade.

PSG.DE stock fundamentals and valuation

PharmaSGP reports trailing EPS €1.68 and market P/E near 17.26, with price-to-sales 3.55 and price-to-book 9.12. The company shows strong margins: gross margin 90.49% and net margin 16.59%, and a conservative balance sheet with debt-to-equity 0.02 and current ratio 2.68. These metrics underline quality earnings but a premium book value, which limits long-term bargain narratives.

PSG.DE stock Meyka grade and forecast

Meyka AI rates PSG.DE with a score out of 100 at 78.99 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year fair value of €27.36, implying a short-term downside of -5.64% versus the current €29.00; forecasts are model-based projections and not guarantees.

PSG.DE stock trading plan, targets and risks

For an oversold bounce trade consider entry near €28.80–€29.00, stop-loss €28.10 and a first target €31.00 for intraday traders. A conservative 12-month target aligned with model upside sits at €31.56 (5-year forecast) while Meyka’s one-year fair value is €27.36. Key risks include inventory turnover weakness (days inventory 400.36) and consumer OTC volatility in the Healthcare sector, which could blunt a sustained rally.

PSG.DE stock sector context and catalysts

PharmaSGP sits in Healthcare, where the sector YTD performance is muted at 0.26% and average PE near 30.68. Catalysts for an oversold bounce include stronger pharmacy sales, cross-border exports recovery and any positive updates on product distribution. Watch sector flows and headline OTC demand across Germany and Europe as near-term directional drivers.

Final Thoughts

PSG.DE stock at €29.00 on XETRA offers a measurable oversold bounce opportunity for tactical traders who accept tight risk control. Intraday volume of 12,424.00 and a relative move back toward the 50-day average €28.52 create a plausible quick gain to a near-term target of €31.00. From a valuation angle the shares trade at P/E 17.26, with Meyka AI’s one-year fair value model at €27.36, implying -5.64% from today’s price; this flags that any tactical long should be size-limited and time-boxed. We present the Meyka grade (B+, 78.99/100, Suggestion: BUY) to frame the setup. This grade factors in benchmark and sector comparisons, financial growth, key metrics and analyst signals. Use a stop near €28.10, trim into strength, and monitor inventory and OTC demand as the primary risk signals. For readers who want the raw quotes and live update, see the company site PharmaSGP and the PSG.DE profile at FinancialModelingPrep. Meyka AI’s analysis is an AI-powered market analysis platform summary and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.